- Amgen (NasdaqGS:AMGN) reported interim Phase 3 data for IMDELLTRA plus IMFINZI in first line extensive stage small cell lung cancer.
- The IMDELLTRA and IMFINZI combination reduced the risk of death and disease progression compared with current standard therapy in the study.
- Investigators reported longer median overall survival and progression free survival for patients receiving the dual immunotherapy regimen.
- There is more to Amgen than the IMDELLTRA and IMFINZI lung cancer data, including risks that investors should understand. We have also spotted 1 warning sign worth knowing about at Amgen.
For readers interested in more ideas linked to this kind of medical and data heavy work, the next stop is 55 AI infrastructure stocks.
Amgen is a large US biotech group with a reported market value of about $237.5b that focuses on discovering and producing human therapeutics, so investors often look at late stage trial readouts like this as signals about how its research pipeline might translate into future treatment options.
4 things going right for Amgen that this headline doesn't cover.
What IMDELLTRA means for Amgen’s oncology upside and its bear-case stress test
For Amgen, these IMDELLTRA and IMFINZI data lean into one of the core bullish arguments in the Narrative, which is that newer oncology biologics can help support a broad earnings base as older drugs face pricing pressure and biosimilar competition. A 58% reduction in risk of death and 66% reduction in risk of progression or death in first line extensive stage small cell lung cancer speaks to market opportunity in a tough indication where treatment options have been limited, and it gives more weight to the idea that Amgen’s oncology franchise can be a meaningful pillar alongside cardiometabolic and rare disease assets.
See how these catalysts shape Amgen's path to a $391 fair value.
Investors now have a clear near term checkpoint. The key marker is how quickly Amgen can translate these Phase 3 results into regulatory filings and, if approved, real world uptake, with attention on any guidance the company gives at upcoming conferences or earnings calls about IMDELLTRA’s initial contribution within the oncology portfolio and how it fits into the mix of the six key growth drivers that already account for nearly 70% of product sales.
One more thing about Amgen that investors cannot see in a trial readout
Clinical headlines only tell part of the story for Amgen. A separate, cash-flow-based estimate of what this enterprise could reasonably be worth exists, and it can be lined up against where the share price trades today. Find out exactly what Amgen is worth today based on its cash flows.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com